# Therapeutic Advances in Medical Oncology

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/therapeutic-advances-in-medical-oncology/

## Facts

| Field | Value |
| --- | --- |
| Open Access | true |
| ISSN-L | 1758-8340 |
| ISSNs | 1758-8340,1758-8359 |
| OpenAlex ID | https://openalex.org/S41085503 |
| Publisher | SAGE Publishing |

## Journal papers

- [5-fluorouracil and cardiotoxicity: a review](https://scholariq.org/papers/5-fluorouracil-and-cardiotoxicity-a-review/)
- [Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies](https://scholariq.org/papers/bone-and-brain-metastasis-in-lung-cancer-recent-advances-in-therapeutic/)
- [A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors](https://scholariq.org/papers/a-systematic-review-and-meta-analysis-of-neurotrophic-tyrosine-receptor-kinase/)
- [Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy](https://scholariq.org/papers/head-and-neck-cancer-the-role-of-anti-egfr-agents-in-the-era-of-immunotherapy/)
- [Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group](https://scholariq.org/papers/real-world-efficacy-and-safety-of-liposomal-irinotecan-plus-fluorouracil/)
- [Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing](https://scholariq.org/papers/academic-oncology-clinicians-understanding-of-biosimilars-and-information-needed/)
- [First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for <i>HER2</i> -altered NSCLC: a retrospective real-world POLISH study](https://scholariq.org/papers/first-line-immunotherapy-or-angiogenesis-inhibitor-plus-chemotherapy-for-i-her2/)
- [Research progress in immune checkpoint inhibitors for lung cancer in China](https://scholariq.org/papers/research-progress-in-immune-checkpoint-inhibitors-for-lung-cancer-in-china/)
- [Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma](https://scholariq.org/papers/isotoxic-high-dose-stereotactic-body-radiotherapy-integrated-in-a-total/)
- [FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial](https://scholariq.org/papers/folfiri-folinic-acid-fluorouracil-and-irinotecan-increases-not-efficacy-but/)
- [First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial](https://scholariq.org/papers/first-line-everolimus-and-cisplatin-in-patients-with-advanced-extrapulmonary/)
- [UFO registry: final analysis of baseline data from patients with advanced prostate cancer in Asia](https://scholariq.org/papers/ufo-registry-final-analysis-of-baseline-data-from-patients-with-advanced/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.